MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01C8B4FF.3EF4A620"

This document is a Single File Web Page, also known as a Web Archive file.  If you are seeing this message, your browser or editor doesn't support Web Archive files.  Please download a browser that supports Web Archive, such as Microsoft Internet Explorer.

------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 11">
<meta name=3DOriginator content=3D"Microsoft Word 11">
<link rel=3DFile-List href=3D"tonsillectomy-080430_files/filelist.xml">
<link rel=3DEdit-Time-Data href=3D"tonsillectomy-080430_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Steroids and Antiobiotics in Tonsillectomy</title>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"place"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"City"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"State"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"country-region"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>UTMB</o:Author>
  <o:LastAuthor>UTMB</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>55</o:TotalTime>
  <o:Created>2008-05-13T18:42:00Z</o:Created>
  <o:LastSaved>2008-05-13T18:42:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>3807</o:Words>
  <o:Characters>22958</o:Characters>
  <o:Company>UTMB</o:Company>
  <o:Lines>417</o:Lines>
  <o:Paragraphs>156</o:Paragraphs>
  <o:CharactersWithSpaces>26609</o:CharactersWithSpaces>
  <o:Version>11.6568</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:SelectEntireFieldWithStartOrEnd/>
   <w:UseWord2002TableStyleRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" LatentStyleCount=3D"156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:AdvMINION-B;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:AdvMINION-R;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:AdvMINION-I;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:AdvP4C4E74;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:HelveticaNeue-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:NewCenturySchlbk-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:NewCenturySchlbk-BoldItalic;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:NewCenturySchlbk-Bold;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:MathematicalPi-Four;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Dutch801BT-Bold;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	font-family:NewCenturySchlbk-Roman;
	mso-font-kerning:0pt;
	font-weight:bold;}
h2
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	text-decoration:underline;
	text-underline:single;}
h3
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	font-style:italic;
	text-decoration:underline;
	text-underline:single;}
h4
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0pt;
	mso-margin-bottom-alt:auto;
	margin-left:0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.volume
	{mso-style-name:volume;}
span.issue
	{mso-style-name:issue;}
span.pages
	{mso-style-name:pages;}
p.GRArial10B, li.GRArial10B, div.GRArial10B
	{mso-style-name:_GR_Arial_10B;
	mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GRCLEARFMT, li.GRCLEARFMT, div.GRCLEARFMT
	{mso-style-name:_GR_CLEAR_FMT;
	mso-style-parent:"";
	mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.GRHeading2, li.GRHeading2, div.GRHeading2
	{mso-style-name:_GR_Heading_2;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:12.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GRHeading3, li.GRHeading3, div.GRHeading3
	{mso-style-name:_GR_Heading_3;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:6.0pt;
	margin-left:0pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	mso-hyphenate:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.GR-No-Indent-Normal, li.GR-No-Indent-Normal, div.GR-No-Indent-Normal
	{mso-style-name:_GR-No-Indent-Normal;
	mso-style-parent:"";
	mso-style-link:"_GR-No-Indent-Normal Char";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:none;
	mso-hyphenate:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRIndent-Normal, li.GRIndent-Normal, div.GRIndent-Normal
	{mso-style-name:_GR_Indent-Normal;
	mso-style-parent:_GR-No-Indent-Normal;
	mso-style-link:"_GR_Indent-Normal Char";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	mso-hyphenate:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRTitle, li.GRTitle, div.GRTitle
	{mso-style-name:_GR_Title;
	mso-style-parent:"";
	mso-style-link:"_GR_Title Char";
	mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.GRTitleChar
	{mso-style-name:"_GR_Title Char";
	mso-style-locked:yes;
	mso-style-link:_GR_Title;
	mso-ansi-font-size:14.0pt;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	mso-bidi-language:AR-SA;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GR-Heading1, li.GR-Heading1, div.GR-Heading1
	{mso-style-name:_GR-Heading_1;
	mso-style-parent:"";
	mso-style-next:Normal;
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	mso-pagination:lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GR-Normal, li.GR-Normal, div.GR-Normal
	{mso-style-name:_GR-Normal;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	mso-hyphenate:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
span.GR-No-Indent-NormalChar
	{mso-style-name:"_GR-No-Indent-Normal Char";
	mso-style-locked:yes;
	mso-style-link:_GR-No-Indent-Normal;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	mso-bidi-language:AR-SA;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
span.GRIndent-NormalChar
	{mso-style-name:"_GR_Indent-Normal Char";
	mso-style-locked:yes;
	mso-style-parent:"_GR-No-Indent-Normal Char";
	mso-style-link:_GR_Indent-Normal;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	mso-bidi-language:AR-SA;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:612.0pt 792.0pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:36.0pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0pt 5.4pt 0pt 5.4pt;
	mso-para-margin:0pt;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3Dpurple style=3D'tab-interval:36.0pt'>

<div class=3DSection1>

<p class=3DGRTitle>TITLE: Steroids and <span class=3DSpellE>Antiobiotics</s=
pan> in
Tonsillectomy<br>
SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology<br>
DATE: April 30, 2008<br>
RESIDENT PHYSICIAN: Ryan W. Ridley, MD<br>
FACULTY PHYSICIAN: <st1:place w:st=3D"on"><st1:City w:st=3D"on"><span class=
=3DSpellE>Jing</span>
  <span class=3DSpellE>Shen</span></st1:City>, <st1:State w:st=3D"on">MD</s=
t1:State></st1:place><br>
SERIES EDITORS: Francis B. Quinn, Jr., MD</p>

<div class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><i><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt'>

<hr size=3D2 width=3D"100%" align=3Dcenter>

</span></i></div>

<p class=3DMsoNormal><i><span style=3D'font-size:10.0pt;mso-bidi-font-size:=
12.0pt'>&quot;This
material was prepared by resident physicians in partial fulfillment of
educational requirements established for the Postgraduate Training Program =
of
the UTMB Department of Otolaryngology/Head and Neck Surgery and was not
intended for clinical use in its present form. It was prepared for the purp=
ose
of stimulating group discussion in a conference setting. No <span class=3DG=
ramE>warranties,</span>
either express or implied, are made with respect to its accuracy, completen=
ess,
or timeliness. The material does not necessarily reflect the current or past
opinions of members of the UTMB faculty and should not be used for purposes=
 of
diagnosis or treatment without consulting appropriate literature sources and
informed professional opinion.&quot; <o:p></o:p></span></i></p>

<div class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><i><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt'>

<hr size=3D2 width=3D"100%" align=3Dcenter>

</span></i></div>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DGR-Heading1>Introduction</p>

<p class=3DGRIndent-Normal>The tonsillectomy is one of the oldest and most
commonly performed surgical procedures today.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>It is estimated that 200,000
tonsillectomies are performed annually in the United States and that
tonsillectomy constitutes a third of operations performed under general
anesthesia in this country.<span style=3D'mso-spacerun:yes'>&nbsp; </span>T=
his
discussion will examine the benefit, or lack thereof, of perioperative ster=
oids
and antibiotics for tonsillectomy.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>In the context of this topic, it will be important to briefly discuss
the history of tonsillectomy, microbiology and mechanisms of action of
dexamethasone and amoxicillin involved in tonsillectomy.</p>

<p class=3DGR-Heading1><span style=3D'mso-spacerun:yes'>&nbsp;</span>Histor=
y</p>

<p class=3DGRIndent-Normal>Tonsillectomy is defined as the complete removal=
 of
the tonsil from its capsule and<span style=3D'mso-spacerun:yes'>&nbsp;&nbsp;
</span>is derived from the Latin word <i>tonsilla,</i> which means a stake =
to
which boats are tied, and the Greek <span class=3DGRIndent-NormalChar>word =
<span
class=3DSpellE>ektome</span> which means excision.<span
style=3D'mso-spacerun:yes'>&nbsp;&nbsp;&nbsp; </span><span class=3DSpellE>A=
ulus</span>
Cornelius <span class=3DSpellE>Celsus</span>, a first century A.D. Roman wr=
iter
and physician gives the earliest account of the removal of the tonsil using=
 a
finger and suggested the use of a knife in situation where the finger proved
ineffective.<span style=3D'mso-spacerun:yes'>&nbsp; </span>He wrote:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>&#8220;<span class=3DGramE>&#8230;=
[</span>tonsils]
should be loosened by scraping around them and then torn out.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>When this is not possible, they sh=
ould
be picked up with a little hook and excised with a scalpel&#8230;.&#8221;<s=
pan
style=3D'mso-spacerun:yes'>&nbsp;&nbsp; </span>Following this description t=
he
methods for tonsillectomy eventually evolved from the use of specialized
knives, wires, strings, <span class=3DSpellE>tonsillotomes</span> and guill=
otines
of the past to the present day techniques.<span style=3D'mso-spacerun:yes'>=
&nbsp;
</span><o:p></o:p></span></p>

<p class=3DGR-Heading1>Tonsillectomy Morbidity</p>

<p class=3DGRIndent-Normal>Despite the evolution of anesthetic and surgical
techniques available, post-tonsillectomy morbidity remains a significant
clinical problem not only for the patient, but the family and physician as
well. Pain is an important morbidity of this procedure, and the current met=
hods
to relieve pain are limited by side effects and outpatient care. Close to 4=
0%
of patients needed to visit their primary care physician or a general physi=
cian
following surgery due to insufficient analgesia.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>A study from the Royal College of
Surgeons of England demonstrated that pain was poorly controlled in 46% of
patients following tonsillectomy.<span style=3D'mso-spacerun:yes'>&nbsp; </=
span>A
study in 1997 found that postoperative pain was more troublesome for the
non-pediatric age group.<span style=3D'mso-spacerun:yes'>&nbsp; </span>An N=
HS
Acute Inpatient Survey submitted by the Picker Institute in May 2003 unveil=
ed
that postoperative pain control is often inadequate with almost two-thirds =
of
patients reporting moderate to severe pain which was not, in the opinions of
27% of patients, adequately managed.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>In addition to pain, nausea, vomiting and inadequate oral intake and
fever are common morbidities encountered after tonsillectomy.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The incidence of vomiting after
tonsillectomy with or without adenoidectomy has a reported range between
40-70%.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The delay in postoper=
ative
oral fluid and solid<span style=3D'mso-spacerun:yes'>&nbsp; </span>intake a=
s a
result of nausea, vomiting, or pain prolongs the time until discharge and a=
lso
increases dehydration risks in early and late postoperative periods. </p>

<p class=3DGR-Heading1>Corticosteroids as a Method to Reduce Post-tonsillec=
tomy
Morbidity</p>

<p class=3DGRIndent-Normal>Methods for reducing pain, nausea, and vomiting =
after
tonsillectomy are important to improve the standard of care our patients
receive.<span style=3D'mso-spacerun:yes'>&nbsp; </span>During the past 35 y=
rs,
investigators have studied the effects of systemic corticosteroids in reduc=
ing
post-tonsillectomy morbidity.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Unfortunately, there is no agreement regarding the routine use of co=
rticosteroids
in tonsillectomy.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Results of
randomized, double-blind, placebo-controlled studies of single dose intrave=
nous
steroids in tonsillectomy have been conflicting; some showing benefit and
others showing no benefit. </p>

<p class=3DGRHeading2><span class=3DSpellE>Dexamethasone</span> as an antie=
metic</p>

<p class=3DGRIndent-Normal>The mechanism of action of dexamethasone as an
antiemetic remains unknown.<span style=3D'mso-spacerun:yes'>&nbsp; </span>S=
ome
postulate that dexamethasone exerts effects either outside the blood-brain
barrier (area postrema of the brainstem) or inside the blood-brain barrier
(vomiting center).<span style=3D'mso-spacerun:yes'>&nbsp; </span>In spite o=
f the
fact that the mechanism is not understood, an antiemetic benefit of
corticosteroids is supported by the literature and widely accepted.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In other trials, dexamethasone has=
 been
shown to be an effective antiemetic in randomized trials with emetogenic
chemotherapy.<span style=3D'mso-spacerun:yes'>&nbsp; </span>In fact, signif=
icant
reduction of emesis after pediatric tonsillectomy was demonstrated in the
dexamethasone-treated group in<span style=3D'mso-spacerun:yes'>&nbsp;
</span>randomized trials of a serotonin antagonist (i.e. odansetron) plus
either dexamethasone or placebo.<span style=3D'mso-spacerun:yes'>&nbsp; </s=
pan></p>

<p class=3DGRHeading2><span class=3DSpellE>Dexamethasone</span> as an
anti-inflammatory </p>

<p class=3DGRIndent-Normal>In conjunction with antiemetic effects, dexameth=
asone
may reduce inflammation at the operative site, subsequently reducing the
release of inflammatory mediators into the circulation.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>This could also lead to less stimu=
lation
of the vomiting center mentioned previously.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Dexamethasone causes inhibition of=
 the
inflammatory response by blocking factors like bradykinin, prostaglandin, a=
nd
leukotrienes which<span style=3D'mso-spacerun:yes'>&nbsp; </span>results in=
 a
decreased level of inflammation and reduction of the accompanying signs and
symptoms including pain.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Also,
dexamethasone can modulate inducible COX-<span class=3DGramE>2 .</span><span
style=3D'mso-spacerun:yes'>&nbsp; </span></p>

<p class=3DGRIndent-Normal>The following is a synopsis of studies that were
highlighted in this presentation that attempt to illustrate the benefit or =
lack
thereof, of steroids in tonsillectomy:</p>

<h2 style=3D'mso-layout-grid-align:auto;text-autospace:ideograph-numeric id=
eograph-other'><span
style=3D'mso-bidi-font-size:12.0pt;mso-bidi-font-weight:normal'>Study #1<o:=
p></o:p></span></h2>

<p class=3DGR-No-Indent-Normal><b>Author:</b><span
style=3D'mso-spacerun:yes'>&nbsp; </span>McKean <i>et al<o:p></o:p></i></p>

<p class=3DGR-No-Indent-Normal><b>Journal</b><i>:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Clinical Otolaryngology </i><b>31<=
/b>,
36-40</p>

<p class=3DGR-No-Indent-Normal><b>Title:</b> &#8220;Use of intravenous ster=
oids
at induction of anesthesia for adult tonsillectomy to reduce post-operative
nausea and vomiting and pain: a double-blind randomized controlled trial&#8=
221;</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Objective</span></b><span style=3D'font-f=
amily:
AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>: </span><span style=3D'font-=
family:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>To assess the effectiveness of
intravenous steroids at induction of anesthetic to <span class=3DGramE>redu=
ce<span
style=3D'mso-spacerun:yes'>&nbsp; </span>post</span>-operative nausea and
vomiting and pain after adult tonsillectomy.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Design:</span></b><span style=3D'font-fam=
ily:
AdvMINION-B;mso-bidi-font-family:AdvMINION-B'><span
style=3D'mso-spacerun:yes'>&nbsp; </span></span><span style=3D'font-family:=
AdvMINION-R;
mso-bidi-font-family:AdvMINION-R'>Prospective, double-blind, randomized,
placebo controlled trial, with ethical approval, following Consolidated
Standards of Reporting Trials guidelines.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Participants</span></b><span
style=3D'font-family:AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>: </span=
><span
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Seventy-=
two
adults between 16 and 70 years, American Association of Anesthetists (ASA) =
1,
listed for elective tonsillectomy.<span style=3D'mso-spacerun:yes'>&nbsp; <=
/span></span><span
style=3D'font-family:AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>Interven=
tion: </span><span
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Single d=
ose of
either 10 mg of dexamethasone or 2 mL of saline after induction with a
consistent anesthetic technique.<span style=3D'mso-spacerun:yes'>&nbsp; </s=
pan><o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-B;mso-b=
idi-font-family:
AdvMINION-B'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Main outcome measures</span></b><span
style=3D'font-family:AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>: </span=
><span
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Patients
filled in a visual analogue scale relating to pain and post-operative nausea
and vomiting for the day of operation and 7 days after operation.<o:p></o:p=
></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'>The time to first ingestion of food and drink after operation =
was
also noted.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Results</span></b><span style=3D'font-fam=
ily:
AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>: </span><span style=3D'font-=
family:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Data completion rate of 64% (=
46
of 72 patients enrolled). Statistically significant relative decrease (62% =
</span><i><span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'>P</span>=
</i><span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'> =3D</sp=
an><span
style=3D'font-family:AdvP4C4E74;mso-bidi-font-family:AdvP4C4E74'> </span><s=
pan
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>0.001) i=
n the
incidence of post-operative nausea and vomiting was seen in those treated w=
ith
dexamethasone. Statistically significant relative decrease (23% </span><i><=
span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'>P</span>=
</i><span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'> =3D</sp=
an><span
style=3D'font-family:AdvP4C4E74;mso-bidi-font-family:AdvP4C4E74'> </span><s=
pan
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>0.016) in
post-operative pain scores for the day of operation was seen in those treat=
ed
with dexamethasone. Significant decrease (17.5%, </span><i><span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'>P</span>=
</i><span
style=3D'font-family:AdvMINION-I;mso-bidi-font-family:AdvMINION-I'> </span>=
<span
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>&lt; 0.0=
01) in
mean pain score for seven post-operative days was seen in those treated with
dexamethasone.<span style=3D'mso-spacerun:yes'>&nbsp; </span>No adverse eff=
ects
were seen.</span><span style=3D'font-family:AdvMINION-B;mso-bidi-font-famil=
y:
AdvMINION-B'><o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-B;
mso-bidi-font-family:AdvMINION-B'>Conclusions</span></b><span style=3D'font=
-family:
AdvMINION-B;mso-bidi-font-family:AdvMINION-B'>: </span><span style=3D'font-=
family:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Dexamethasone given as a sing=
le
dose of 10 mg at induction of anesthesia for adult tonsillectomy is an
effective, safe and inexpensive method for reducing<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:AdvMINION-R;
mso-bidi-font-family:AdvMINION-R'>morbidity</span></span><span
style=3D'font-family:AdvMINION-R;mso-bidi-font-family:AdvMINION-R'> in adult
tonsillectomy.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:AdvMINION-R;mso-b=
idi-font-family:
AdvMINION-R'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:12.0pt;fon=
t-family:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'>Study #2<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-R;
mso-bidi-font-family:AdvMINION-R'>Author:</span></b><span style=3D'font-fam=
ily:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'><span
style=3D'mso-spacerun:yes'>&nbsp; </span>Kaan <i>et al</i><o:p></o:p></span=
></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-R;
mso-bidi-font-family:AdvMINION-R'>Journal:</span></b><span style=3D'font-fa=
mily:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'><span
style=3D'mso-spacerun:yes'>&nbsp; </span><i>International Journal of Pediat=
ric
Otorhinolaryngology</i> (2006) <b>70</b>: 73-79<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:AdvMINION-R;
mso-bidi-font-family:AdvMINION-R'>Title:</span></b><span style=3D'font-fami=
ly:
AdvMINION-R;mso-bidi-font-family:AdvMINION-R'><span
style=3D'mso-spacerun:yes'>&nbsp; </span>&#8220;</span>The effect of preope=
rative
dexamethasone on early oral intake, vomiting and pain after
tonsillectomy&#8221;</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Objective</b>: Postoperative morbidity in
patients undergoing tonsillectomy with or</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>without</span> adenoidec=
tomy
includes inadequate oral intake, pain, nausea, vomiting</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>and</span> bleeding. The=
 purpose
of this study is to evaluate the effect of preoperative 0.5 mg/kg intraveno=
us
dexamethasone on postoperative early oral intake, pain, vomiting in patients
undergoing adenotonsillectomy while performing standard anesthesia technique
and sharp dissection tonsillectomy.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Methods</b>: In this prospective,
double-blinded, placebo-controlled study 62 children,</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>aged</span> 4&#8212;12 y=
ears,
who underwent tonsillectomy with or without adenoidectomy were</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>randomly</span> assigned=
 to
receive single dose of 0.5 mg/kg intravenous dexamethasone preoperatively.
Patients started to receive 100 ml of clear fluids 2 h postoperatively, <sp=
an
class=3DGramE>then</span> were offered every hour. When pain score was 3 or
above, paracetamol was given for pain control. Tolerating 400 ml of clear
fluids, no bleeding and no vomiting were accepted as discharge criteria. The
discharge time was also recorded. The incidence of early vomiting, pain sco=
res,
amount of oral intake were recorded until the discharge time.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Results</b>: Compared with placebo, the
patients who received preoperative <span class=3DGramE>dexamethasone</span>=
</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>had</span> significantly=
 less
pain score during the first 6 h postoperatively ( p &lt; 0.05),</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>adequate</span> amount o=
f oral
intake time was shorter ( p &lt; 0.05) and the discharge time</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>was</span> earlier ( p &=
lt;
0.05). No difference was found in vomiting incidence in both groups.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Conclusion</b>: Preoperative dexamethason=
e use
significantly reduces early post-tonsillectomy pain, improves oral intake a=
nd
facilitates meeting the discharge criteria while using standard anesthesia
technique and sharp dissection tonsillectomy without any</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>significant</span> side =
effects.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:12.0pt'>St=
udy #3<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><b>Author: </b>Steward <i>et al</i>,</p>

<p class=3DGR-No-Indent-Normal><b>Journal:</b><span
style=3D'mso-spacerun:yes'>&nbsp; </span><i>Laryngoscope</i><span
style=3D'font-family:HelveticaNeue-Roman;mso-bidi-font-family:HelveticaNeue=
-Roman'>
</span>111: October 2001</p>

<p class=3DGR-No-Indent-Normal><b>Title: &#8220;</b><span style=3D'font-fam=
ily:
NewCenturySchlbk-Roman;mso-bidi-font-family:NewCenturySchlbk-Roman'>Do Ster=
oids
Reduce Morbidity of Tonsillectomy? Meta-Analysis of Randomized Trials&#8221=
;<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Roman;
mso-bidi-font-family:NewCenturySchlbk-Roman'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>Objectives/Hypothesis</sp=
an></b><i><span
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>:
</span></i><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-f=
amily:
NewCenturySchlbk-Bold'>The study aims to reconcile conflicting published
reports regarding the clinical efficacy of a single intraoperative dose of
dexamethasone<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:NewCenturySchlbk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>in</span></span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>
reducing post-tonsillectomy morbidity.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>Study Design</span></b><i=
><span
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>:
</span></i><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-f=
amily:
NewCenturySchlbk-Bold'>Systematic overview (meta-analysis).<o:p></o:p></spa=
n></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>Methods:</span></b><i><sp=
an
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>
</span></i><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-f=
amily:
NewCenturySchlbk-Bold'>To critically evaluate the existing evidence, the
authors performed a formal meta-analysis of eight double-blinded, randomize=
d,
placebo-controlled studies of<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:NewCenturySchlbk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>dexamethasone</span></span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>
in pediatric patients undergoing tonsillectomy or adenotonsillectomy. <span
class=3DGramE>Reduction in postoperative emesis and pain, as well as early =
return
to soft or solid diet, were</span> studied as distinct end points. <o:p></o=
:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>Results</span></b><i><span
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>:
</span></i><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-f=
amily:
NewCenturySchlbk-Bold'>Children being given a single intraoperative dose of
dexamethasone (dosing, 0.15&#8211;1.0 mg/kg; maximum dose, 8&#8211;25 mg) w=
ere
two times less likely to vomit in the first 24 hours than children being gi=
ven
placebo (relative risk [RR] =3D</span><span style=3D'font-family:Mathematic=
alPi-Four;
mso-bidi-font-family:MathematicalPi-Four'> </span><span style=3D'font-famil=
y:
NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturySchlbk-Bold'>0.55; 95%
confidence interval [CI], 0.41&#8211;0.74; </span><i><span style=3D'font-fa=
mily:
NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCenturySchlbk-BoldItali=
c'>P
</span></i><span style=3D'font-family:Dutch801BT-Bold;mso-bidi-font-family:=
Dutch801BT-Bold'>&lt;</span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>.0001).
Routine use in four children would be expected to result in one less patient
having post-tonsillectomy emesis (risk difference [RD] =3D -0.24; 95% CI, -=
0.38
to -0.10; </span><i><span style=3D'font-family:NewCenturySchlbk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>P=3D</span></i><span
style=3D'font-family:MathematicalPi-Four;mso-bidi-font-family:MathematicalP=
i-Four'>
</span><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-famil=
y:
NewCenturySchlbk-Bold'>.0006).<span style=3D'mso-spacerun:yes'>&nbsp; </spa=
n>In
addition, children being given dexamethasone<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:NewCenturySchlbk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>were</span></span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>
more likely to advance to a soft or solid diet on post-tonsillectomy day 1 =
(RR=3D</span><span
style=3D'font-family:MathematicalPi-Four;mso-bidi-font-family:MathematicalP=
i-Four'>
</span><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-famil=
y:
NewCenturySchlbk-Bold'>1.69; 95% CI, 1.02&#8211;2.79; </span><i><span
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>P=3D</span></i><span
style=3D'font-family:MathematicalPi-Four;mso-bidi-font-family:MathematicalP=
i-Four'>
</span><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-famil=
y:
NewCenturySchlbk-Bold'>.04) than those being given placebo. Because of<o:p>=
</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:NewCenturySchlbk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>missing</span></span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>
data and varied outcome measures, pain could not be meaningfully analyzed a=
s a
distinct end point. <o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-BoldItalic;
mso-bidi-font-family:NewCenturySchlbk-BoldItalic'>Conclusion:</span></b><i>=
<span
style=3D'font-family:NewCenturySchlbk-BoldItalic;mso-bidi-font-family:NewCe=
nturySchlbk-BoldItalic'>
</span></i><span style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-f=
amily:
NewCenturySchlbk-Bold'>Given the frequency of tonsillectomy, relative safety
and low cost of dexamethasone, and the reduction in postoperative morbidity,
the authors recommend<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'font-fami=
ly:NewCenturySchlbk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>routine</span></span><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>
use of a single intravenous dose during pediatric tonsillectomy.<o:p></o:p>=
</span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'font-family:NewCenturySchlbk-=
Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:12.0pt;fon=
t-family:
NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturySchlbk-Bold'>Study #4<=
o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>Author:</span></b><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'><span
style=3D'mso-spacerun:yes'>&nbsp; </span>Lachance et al<o:p></o:p></span></=
p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'font-family:NewCenturySchl=
bk-Bold;
mso-bidi-font-family:NewCenturySchlbk-Bold'>Journal</span></b><span
style=3D'font-family:NewCenturySchlbk-Bold;mso-bidi-font-family:NewCenturyS=
chlbk-Bold'>:<span
style=3D'mso-spacerun:yes'>&nbsp; </span></span><i>Laryngoscope </i><b>118<=
/b>:
February 2008</p>

<p class=3DGR-No-Indent-Normal><b>Title</b>:<span style=3D'mso-spacerun:yes=
'>&nbsp;
</span>&#8220;The Use of Dexamethasone to Reduce Pain After Tonsillectomy in
Adults:</p>

<p class=3DGR-No-Indent-Normal>A Double-Blind Prospective Randomized Trial&=
#8221;</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Objectives/Hypothesis: </b>To determine t=
he
effectiveness of dexamethasone to reduce pain after tonsillectomy in adults=
 by
at least 13 mm on the visual analogue</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>scale</span>. The second=
ary
objective was to reduce the use of narcotics by at least 20%.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Study Design: </b>This multicentric study=
 is a
prospective double-blind randomized controlled trial.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Methods: </b>A total of 102 patients were
enrolled and received a 4-day trial either of dexamethasone in decreasing d=
oses
or placebo. The patients were asked to note the</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>level</span> of pain on =
the
visual analogue scale daily for 7 days.<span style=3D'mso-spacerun:yes'>&nb=
sp;
</span>They also had to record their consumption of analgesic and any event=
ual
side effects.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Results: </b>There were no statistically =
or
clinically significant differences between the two groups for the level of =
pain
noted on the visual analogue scale for the first 4 and 7 days. There were no
statistical differences for the consumption of hydromorphone between the two
groups. </p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><b>Conclusion: </b>The authors do not recomm=
end
the use of dexamethasone on a routine basis following tonsillectomy in adul=
ts
for the reduction of pain or narcotics consumption.</p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DGRIndent-Normal><span class=3DSpellE>Dexamethasone</span> is the=
 most
powerful anti-inflammatory steroid with the advantage <span class=3DGramE>o=
f<span
style=3D'mso-spacerun:yes'>&nbsp; </span>a</span> long half-life.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Use of this drug for less than 2 w=
eeks
is considered safe even in supraphysiologic doses.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Complications from corticosteroid
therapy such as increased infection rates, peptic ulcers, and adrenal
suppression are usually related to prolonged use.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The risk of steroid therapy for a =
single
dose or for<span style=3D'mso-spacerun:yes'>&nbsp; </span>less than 24 hrs =
is
negligible.<span style=3D'mso-spacerun:yes'>&nbsp; </span>There are no repo=
rts in
the literature of complications from use of intravenous dexamethasone during
pediatric tonsillectomy.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The =
use of
dexamethasone, if proven useful like the above mentioned studies, would all=
ow
pain relief, decreased use of narcotics, <span class=3DGramE>decreased</spa=
n>
frequency of unscheduled consultation and decrease the social costs of this
surgery by a faster return to work.</p>

<p class=3DGR-Heading1>Role of Infection and Antiobiotics in Post-tonsillec=
tomy
Morbidity</p>

<p class=3DGRIndent-Normal>According to O&#8217;Reilly et al, the most sign=
ificant
post-tonsillectomy morbidity is due to bleeding and pain.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Secondary hemorrhage is now more c=
ommon
than primary hemorrhage, particularly in the adult population.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The reason for secondary hemorrhag=
e is
not understood completely, but is often attributed to infection.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Gaffney and Cafferkey<span
style=3D'mso-spacerun:yes'>&nbsp; </span>illustrated the presence of organi=
sms
within the tonsils of patients with recurrent tonsillitis and that amoxicil=
lin
could reduce their concentration.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Below is the table of results of tonsil core swabs of children who h=
ad
recurrent acute tonsillitis from this study:</p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><!--[if gte vml 1]><v:shapetype
 id=3D"_x0000_t75" coordsize=3D"21600,21600" o:spt=3D"75" o:preferrelative=
=3D"t"
 path=3D"m@4@5l@4@11@9@11@9@5xe" filled=3D"f" stroked=3D"f">
 <v:stroke joinstyle=3D"miter"/>
 <v:formulas>
  <v:f eqn=3D"if lineDrawn pixelLineWidth 0"/>
  <v:f eqn=3D"sum @0 1 0"/>
  <v:f eqn=3D"sum 0 0 @1"/>
  <v:f eqn=3D"prod @2 1 2"/>
  <v:f eqn=3D"prod @3 21600 pixelWidth"/>
  <v:f eqn=3D"prod @3 21600 pixelHeight"/>
  <v:f eqn=3D"sum @0 0 1"/>
  <v:f eqn=3D"prod @6 1 2"/>
  <v:f eqn=3D"prod @7 21600 pixelWidth"/>
  <v:f eqn=3D"sum @8 21600 0"/>
  <v:f eqn=3D"prod @7 21600 pixelHeight"/>
  <v:f eqn=3D"sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok=3D"f" gradientshapeok=3D"t" o:connecttype=3D"rect"/>
 <o:lock v:ext=3D"edit" aspectratio=3D"t"/>
</v:shapetype><v:shape id=3D"_x0000_i1027" type=3D"#_x0000_t75" style=3D'wi=
dth:236.25pt;
 height:135.75pt'>
 <v:imagedata src=3D"tonsillectomy-080430_files/image001.png" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D315 height=3D181
src=3D"tonsillectomy-080430_files/image002.jpg" v:shapes=3D"_x0000_i1027"><=
![endif]></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'>The
same article also had a chart showing the bacteriology of the tonsil core
of<span style=3D'mso-spacerun:yes'>&nbsp; </span>5 adults who also had recu=
rrent
acute tonsillitis:</p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><span
style=3D'font-size:10.0pt;font-family:HelveticaNeue-Roman;mso-bidi-font-fam=
ily:
HelveticaNeue-Roman'><!--[if gte vml 1]><v:shape id=3D"_x0000_i1028" type=
=3D"#_x0000_t75"
 style=3D'width:236.25pt;height:43.5pt'>
 <v:imagedata src=3D"tonsillectomy-080430_files/image003.png" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D315 height=3D58
src=3D"tonsillectomy-080430_files/image004.jpg" v:shapes=3D"_x0000_i1028"><=
![endif]><o:p></o:p></span></p>

<p class=3DGRHeading2><span style=3D'font-family:NewCenturySchlbk-Roman;mso=
-bidi-font-family:
NewCenturySchlbk-Roman'><o:p>&nbsp;</o:p></span></p>

<p class=3DGRHeading2><a name=3Dmechanism><span style=3D'font-family:NewCen=
turySchlbk-Roman;
mso-bidi-font-family:NewCenturySchlbk-Roman'>Amoxicillin </span>Mechanism of
Action:</a></p>

<p class=3DGRIndent-Normal><span style=3D'mso-bookmark:mechanism'><span
style=3D'mso-spacerun:yes'>&nbsp;</span>Beta-lactam antibiotics such as
amoxicillin are mainly bactericidal. Like other penicillins, amoxicillin
inhibits the third and final stage of bacterial cell wall synthesis by
preferentially binding to specific penicillin-binding proteins (PBPs) that =
are
located inside the bacterial cell wall. Penicillin-binding proteins are
responsible for several steps in the synthesis of the cell wall and are fou=
nd
in quantities of several hundred to several thousand molecules per bacterial
cell. Penicillin-binding proteins vary among different bacterial species. T=
hus,
the intrinisic activity of amoxicillin, as well as the other penicillins,
against a particular organism depends on their ability to gain access to and
bind with the necessary PBP. The aminopenicillins are able to penetrate gra=
m-negative
bacteria more readily than are the natural penicillins or
penicillinase-resistant penicillins due to the presence of a free amino gro=
up
within the structure. Like all beta-lactam antibiotics, amoxicillin's abili=
ty
to interfere with PBP-mediated cell wall synthesis ultimately leads to cell
lysis. Lysis is mediated by bacterial cell wall autolytic enzymes (i.e.,
autolysins). The relationship between PBPs and autolysins is unclear, but i=
t is
possible that the beta-lactam antibiotic interferes with an autolysin
inhibitor.</span></p>

<p class=3DGRHeading2><span style=3D'mso-bookmark:mechanism'>Amoxicillin sp=
ectrum
of activity</span></p>

<p class=3DGRIndent-Normal><span style=3D'mso-bookmark:mechanism'>Amoxicill=
in's
gram-positive spectrum is similar to the natural penicillins, although
amoxicillin is slightly less active than penicillin G against <i>S. pyogene=
s</i>,
<i>S. pneumoniae</i>, <i>S. and agalactiae</i> and slightly more active aga=
inst
enterococci.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Gram-negative ba=
cteria
that are frequently susceptible include <i>N. meningitidis, H. influenzae,
Gardnerella vaginalis, Bordetella pertussis, </i>and some enteric bacilli
including <i>E. coli, Proteus mirabilis,</i> and <i>Salmonella</i>.</span><=
/p>

<p class=3DGRHeading2><span style=3D'mso-bookmark:mechanism'>Amoxicillin-Cl=
avulanate
(aka Augmentin)</span></p>

<p class=3DGRIndent-Normal><span style=3D'mso-bookmark:mechanism'>The mecha=
nism of
action of Augmentin is the same as amoxicillin mentioned above.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The clavulanic acid is a beta-lact=
am
drug that acts as a competitive &quot;suicide&quot; inhibitor of many
plasmid-mediated and chromosomally mediated bacterial beta-lactamases. Like
sulbactam, clavulanic acid inhibits the activity of beta-lactamase Richmond
types II, III, IV, V, and VI. It will not inhibit chromosomal type I, howev=
er,
found in some Enterbacteriaceae. Clavulanic acid binds to the enzyme's acti=
ve
site, inactivating the beta-lactamase. Clavulanic acid can penetrate the ce=
ll
wall and inactivate bound, as well as extracellular, beta-lactamases. It do=
es
not, however, overcome methicillin-resistance in staphylococci since this i=
s mediated
via a different mechanism. Clavulanic acid does not alter the actions of the
beta-lactam antibiotics. It exhibits weak antibacterial effects.<span
style=3D'mso-spacerun:yes'>&nbsp; </span></span></p>

<p class=3DGRHeading2><span style=3D'mso-bookmark:mechanism'>Augmentin spec=
trum of
activity</span></p>

<span style=3D'mso-bookmark:mechanism'></span>

<p class=3DGRIndent-Normal>Organisms that are susceptible to ampicillin and=
 plain
amoxicillin are also susceptible to Augmentin. Augmentin has an expanded
gram-positive spectrum that includes the beta-lactamase- producing
staphylococci and most streptococci including enterococcus.
Methicillin-resistant staphylococci (MRSA) are not susceptible. Penicillin-=
resistant
strains of <i>S. pneumoniae</i> are increasing in number. The mechanism of
resistance is mediated via the development of altered PBPs and the
penicillin-resistant strains will generally be resistant to amoxicillin. The
addition of clavulanic acid does not overcome this type of resistance.
Increased dosages of amoxicillin may be necessary to overcome
penicillin-resistant <i>S. pneumoniae</i>. The gram-negative spectrum of
Augmentin includes <i>N. gonorrhoeae, N. meningitidis, Moraxella (Branhamel=
la)
catarrhalis, H. influenzae, H. ducreyi, Gardnerella vaginalis, Bordetella
pertussis, </i>and some enteric bacilli including <i>E. coli, Klebsiella
pneumoniae, Proteus mirabilis,</i> and <i>Salmonella</i>. Augmentin is
extremely active against many anaerobic bacteria since many of these organi=
sms
liberate beta-lactamases.<span style=3D'font-family:NewCenturySchlbk-Roman;
mso-bidi-font-family:NewCenturySchlbk-Roman'><o:p></o:p></span></p>

<p class=3DGR-Heading1>Current Debate over Antibiotics in Tonsillectomy</p>

<p class=3DGRIndent-Normal>For the past 18 yrs, investigators have analyzed=
 the
use of antibiotics to reduce post-tonsillectomy morbidity, showing no clear
consensus.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Data from randomiz=
ed
studies have demonstrated conflicting results with some showing a clinical
benefit whereas others fail to show any benefit.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The following is a brief synopsis =
of
articles that investigate antibiotics effects on post-tonsillectomy morbidi=
ty:</p>

<p class=3DGR-No-Indent-Normal><b><u>Study #1<o:p></o:p></u></b></p>

<p class=3DGR-No-Indent-Normal>Author: Burkhart and Steward</p>

<p class=3DGR-No-Indent-Normal>Journal: <i><span style=3D'mso-bidi-font-siz=
e:9.0pt'>Laryngoscope</span></i><span
style=3D'mso-bidi-font-size:9.0pt'> 115: June 2005</span></p>

<p class=3DGR-No-Indent-Normal>Title:<span style=3D'mso-spacerun:yes'>&nbsp;
</span>&#8220;<span style=3D'mso-bidi-font-size:24.0pt'>Antibiotics for Red=
uction
of Post-tonsillectomy Morbidity: A Meta-Analysis&#8221;<o:p></o:p></span></=
p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:24.0pt'><o=
:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Objective</span></b><i><span
style=3D'mso-bidi-font-size:9.0pt'>: </span></i><span style=3D'mso-bidi-fon=
t-size:
9.0pt'>To reconcile conflicting published reports regarding the clinical
efficacy of postoperative antibiotics for reduction of post-tonsillectomy
morbidity. <o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Study
Design</span></b><i><span style=3D'mso-bidi-font-size:9.0pt'>: </span></i><=
span
style=3D'mso-bidi-font-size:9.0pt'>Systematic review (meta-analysis). <o:p>=
</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Methods</span></b><i><span
style=3D'mso-bidi-font-size:9.0pt'>: </span></i><span style=3D'mso-bidi-fon=
t-size:
9.0pt'>Meta-analysis of seven randomized controlled trials of postoperative
oral<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'mso-bidi-=
font-size:
9.0pt'>antibiotics</span></span><span style=3D'mso-bidi-font-size:9.0pt'> in
patients undergoing tonsillectomy or adenotonsillectomy. Postoperative pain=
 and
time to return to normal activity and diet were studied as distinct end poi=
nts
using a random effects model with weighted mean difference (Rev-Man 4.2).
Search strategy included electronic searches of PubMed and Cochrane library
databases;<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'mso-bidi-=
font-size:
9.0pt'>cross-referencing</span></span><span style=3D'mso-bidi-font-size:9.0=
pt'>
textbooks, reviews, and original trials; and contacting experts in the fiel=
d.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Results</span></b><i><span
style=3D'mso-bidi-font-size:9.0pt'>: </span></i><span style=3D'mso-bidi-fon=
t-size:
9.0pt'>Subjects treated with antibiotics experienced an earlier return to a
normal diet<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'>(-1=
.22
days; 95% confidence interval [CI<span class=3DGramE>]=3D</span> -1.97, -0.=
48; <i>P=3D</i>
.001) and an earlier return to normal activity (-0.99 days; 95% CI=3D -1.80,
-0.17; <i>P=3D</i> .02). Evaluation of mean pain visual analogue scores (VAS
0&#8211;10) over the first 5 and 7 postoperative days failed to demonstrate=
 any
significant effect of antibiotic therapy (VAS difference over 5 days =3D<o:=
p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'>0.4=
1;
-1.18, 2.00; <i>P =3D</i> .61) (VAS difference over 7 days =3D -0.64; -3.46=
, 2.18; <i>P=3D</i>
.66). Cost analysis suggests routine therapy may be cost-effective but did =
not
include analysis of side effects or resistance resulting from antibiotic us=
age.
<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Conclusion</span></b><i><span
style=3D'mso-bidi-font-size:9.0pt'>: </span></i><span style=3D'mso-bidi-fon=
t-size:
9.0pt'>The results of this systematic meta-analysis suggest that postoperat=
ive
oral antibiotics do not significantly reduce post-tonsillectomy pain but re=
sult
in an earlier return to normal activity and diet by approximately 1 day. Gi=
ven
the frequency<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'mso-bidi-=
font-size:
9.0pt'>that</span></span><span style=3D'mso-bidi-font-size:9.0pt'> tonsille=
ctomy
is performed, this possible benefit should be weighed against the cost and
potential side effects of routine antibiotic therapy.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><u>Study#2<o:p></o:p></u></b></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'>Aut=
hor:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>O&#8217;Reilly <i>et al</i><o:p></=
o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'>Jou=
rnal:<span
style=3D'mso-spacerun:yes'>&nbsp; </span></span><i><span style=3D'mso-bidi-=
font-size:
8.0pt'>The Journal of Laryngology &amp; Otology </span></i><span
style=3D'mso-bidi-font-size:8.0pt'>May 2003, Vol. 117, pp. 382&#8211;385</s=
pan><span
style=3D'mso-bidi-font-size:9.0pt'><o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'>Tit=
le: </span><span
style=3D'mso-spacerun:yes'>&nbsp;</span>&#8220;<span style=3D'mso-bidi-font=
-size:
16.5pt'>Is the routine use of antibiotics justified in adult
tonsillectomy?&#8221;<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:16.5pt'><o=
:p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Objective</span></b><span
style=3D'mso-bidi-font-size:9.0pt'>:<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Assess the effect of perioperative amoxicillin on the complications =
of
pain and secondary hemorrhage.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Design</span></b><span
style=3D'mso-bidi-font-size:9.0pt'>: This is a randomized, double-blind, pl=
acebo-controlled,
prospective trial<span style=3D'mso-spacerun:yes'>&nbsp; </span><o:p></o:p>=
</span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Outcome
measures</span></b><span style=3D'mso-bidi-font-size:9.0pt'>: The incidence=
 and
severity of post-operative hemorrhage was measured as well as postoperative
pain.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Methods</span></b><span
style=3D'mso-bidi-font-size:9.0pt'>: For the first 10 post-operative days
patients provided a linear pain score, a<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'mso-bidi-=
font-size:
9.0pt'>record</span></span><span style=3D'mso-bidi-font-size:9.0pt'> of GP =
visits,
and their use of additional antibiotics and analgesics.<o:p></o:p></span></=
p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Results</span></b><span
style=3D'mso-bidi-font-size:9.0pt'>: Of 95 patients considered: 23 suffered=
 a
secondary hemorrhage; 54 consulted their general practitioner (GP) because =
of
pain; additional antibiotics were used by at least 31 and additional analge=
sics
by at least 41. <o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:9.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><b><span style=3D'mso-bidi-font-size:9.0pt'>=
Conclusions</span></b><span
style=3D'mso-bidi-font-size:9.0pt'>: No significant differences were demons=
trated
between the active and placebo groups for any of these measures. This study
demonstrates that secondary hemorrhage is common after adult tonsillectomy.
Postoperative pain remains a major problem requiring frequent GP consultati=
ons.
There appears to be no justification for the routine use of perioperative
antibiotics<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><span
style=3D'mso-bidi-font-size:9.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=3DGRIndent-Normal>Although there may be some benefits with
post-tonsillectomy use of antibiotics, these need to be weighed against the
potential side effects of the medications. Although the antibiotics are bei=
ng
used to possibly decrease morbidity resulting from tonsillectomy, a fairly
significant percentage of patients will likely be subject to adverse effect=
s of
the medication with the most prevalent being diarrhea.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>This is especially common with
Augmentin.<span style=3D'mso-spacerun:yes'>&nbsp; </span>However, more
life-threatening effects are rare.</p>

<h3>Summary</h3>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><b><i><u><span
style=3D'mso-bidi-font-size:9.0pt'><o:p><span style=3D'text-decoration:none=
'>&nbsp;</span></o:p></span></u></i></b></p>

<p class=3DMsoNormal style=3D'mso-layout-grid-align:none;text-autospace:non=
e'><span
style=3D'mso-bidi-font-size:9.0pt'>Children who receive dexamethasone
perioperatively<span style=3D'mso-spacerun:yes'>&nbsp; </span>during
tonsillectomy usually have less morbidity than those who do not receive
dexamethasone, especially a reduction in nausea/vomiting.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>As for adults, there have been stu=
dies
using a single dose of intraoperative dexamethasone (although few) that
demonstrate a reduction in postoperative morbidity.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Important to note, however; is the=
 fact
that this benefit is not evident when the steroids are given as a postopera=
tive
course.<span style=3D'mso-spacerun:yes'>&nbsp; </span>When it comes to
antibiotics in both populations, it seems that pain is not significantly re=
duced
although earlier returns to normal diet and activity are achieved.<span
style=3D'mso-spacerun:yes'>&nbsp;&nbsp; </span><o:p></o:p></span></p>

<b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:14.0pt;
mso-bidi-font-size:10.0pt;font-family:Arial;mso-fareast-font-family:"Times =
New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DGR-Heading1>BIBLIOGRAPHY</p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/11801931?ordinalpos=3D2&amp;itoo=
l=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>Steward=
 DL,
Welge JA, Myer CM.</span></a><span style=3D'mso-spacerun:yes'>&nbsp; </span=
>Do
steroids reduce morbidity of tonsillectomy? Meta-analysis of randomized tri=
als.
<i>Laryngoscope</i>. 2001 Oct<span class=3DGramE>;<span class=3Dvolume>111<=
/span></span>(<span
class=3Dissue>10</span>):<span class=3Dpages>1712-8</span>. </p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/15979735?ordinalpos=3D12&amp;ito=
ol=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>Kaan MN,
Odabasi O, Gezer E, Daldal A.</span></a> The effect of preoperative
dexamethasone on early oral intake, vomiting and pain after tonsillectomy. =
<i>Int
J Pediatr Otorhinolaryngol</i>. 2006 Jan<span class=3DGramE>;<span class=3D=
volume>70</span></span>(<span
class=3Dissue>1</span>):<span class=3Dpages>73-9</span>.</p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/18043492?ordinalpos=3D18&amp;ito=
ol=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>Lachanc=
e M,
Lacroix Y, Audet N<span class=3DGramE>, Savard P, Thuot F.</span></span></a=
><span
class=3DGramE> </span><span style=3D'mso-spacerun:yes'>&nbsp;</span>The use=
 of
dexamethasone to reduce pain after tonsillectomy in adults: a double-blind
prospective randomized trial.</p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><i>Laryngoscope</i>.</sp=
an> 2008
Feb<span class=3DGramE>;<span class=3Dvolume>118</span></span>(<span class=
=3Dissue>2</span>):<span
class=3Dpages>232-6</span></p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/16441800?ordinalpos=3D20&amp;ito=
ol=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>McKean =
S,
Kochilas X, Kelleher R, <span class=3DGramE>Dockery</span> M.</span></a> Us=
e of
intravenous steroids at induction of anaesthesia for adult tonsillectomy to
reduce post-operative nausea and vomiting and pain: a double-blind randomiz=
ed
controlled trial. <i>Clin Otolaryngol</i>. 2006 Feb<span class=3DGramE>;<sp=
an
class=3Dvolume>31</span></span>(<span class=3Dissue>1</span>):<span class=
=3Dpages>36-40<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3Dpages><o:p>&nbsp;</o:p></span>=
</p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/11493216?ordinalpos=3D25&amp;ito=
ol=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>Heatley=
 DG.</span></a><span
style=3D'mso-spacerun:yes'>&nbsp; </span><span class=3DGramE>Perioperative
intravenous steroid treatment and tonsillectomy.</span></p>

<p class=3DGR-No-Indent-Normal><i>Arch Otolaryngol Head Neck Surg.</i> 2001=
 Aug<span
class=3DGramE>;<span class=3Dvolume>127</span></span>(<span class=3Dissue>8=
</span>):<span
class=3Dpages>1007-8</span>. </p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/12803788?ordinalpos=3D3&amp;itoo=
l=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>O'Reill=
y BJ,
Black S, Fernandes J, Panesar J.</span></a><span
style=3D'mso-spacerun:yes'>&nbsp; </span><span class=3DGramE>Is</span> the =
routine
use of antibiotics justified in adult tonsillectomy? <i>J Laryngol Otol</i>.
2003 May<span class=3DGramE>;<span class=3Dvolume>117</span></span>(<span
class=3Dissue>5</span>):<span class=3Dpages>382-5<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span class=3Dpages><o:p>&nbsp;</o:p></span>=
</p>

<p class=3DGR-No-Indent-Normal><a
href=3D"http://www.ncbi.nlm.nih.gov/pubmed/15933509?ordinalpos=3D9&amp;itoo=
l=3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum"><span
style=3D'color:windowtext;text-decoration:none;text-underline:none'>Burkart=
 CM,
Steward DL.</span></a><span style=3D'mso-spacerun:yes'>&nbsp; </span>Antibi=
otics
for reduction of posttonsillectomy morbidity: a meta-analysis. <span
class=3DGramE><i>Laryngoscope.</i></span> 2005 Jun<span class=3DGramE>;<span
class=3Dvolume>115</span></span>(<span class=3Dissue>6</span>):<span class=
=3Dpages>997-1002</span></p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE>Gaffney R.J. and Cafferk=
y M.T.</span><span
style=3D'mso-spacerun:yes'>&nbsp; </span>Bacteriology of normal and diseased
tonsils assessed by fine needle aspiration:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Haemophilus influenzae and the
pathogenesis of recurrent acute tonsillitis.<span
style=3D'mso-spacerun:yes'>&nbsp; </span><span class=3DGramE><i>Clin.</i></=
span><i>
<span class=3DGramE>Otolaryngol<span style=3D'font-style:normal;mso-bidi-fo=
nt-style:
italic'>.</span></span></i> 1998, <b>23</b>,181-185</p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-spacerun:yes'>&nbsp; </sp=
an></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'>S.R=
. Furst,
A. Rodarte, Prophylactic antiemetic treatment with ondansetron in children
undergoing tonsillectomy, <i>Anesthesiology</i> 81 (1994) 799&#8212;803<o:p=
></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'>R.S.
Litman, C.L. WU, F.A. Catanzaro, Ondansetron decreases emesis after
tonsillectomy in children, <i>Anesth. <span class=3DGramE>Analg<span
style=3D'font-style:normal;mso-bidi-font-style:italic'>.</span></span></i> =
78
(1994) 478&#8212;481</span></p>

<p class=3DGR-No-Indent-Normal><o:p>&nbsp;</o:p></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'>L.R.
Ferrari, J.V. Donlon, Metoclopramide reduces the incidence<o:p></o:p></span=
></p>

<p class=3DGR-No-Indent-Normal><span class=3DGramE><span style=3D'mso-bidi-=
font-size:
8.0pt'>of</span></span><span style=3D'mso-bidi-font-size:8.0pt'> vomiting a=
fter
tonsillectomy in children, <i>Anesth. <span class=3DGramE>Analg<span
style=3D'font-style:normal;mso-bidi-font-style:italic'>.</span></span></i> =
<span
class=3DGramE>75 (1992) 351&#8212;354.</span><o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'>Llo=
yd
Faulconbridge RV, Fowler S, Horrocks J, et al. Comparative audit of
tonsillectomy. <i>Clin Otolaryngol </i>2000<span class=3DGramE>;25</span>:
110&#8211;117.<o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.0pt'><o:=
p>&nbsp;</o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.5pt'>Dep=
artment
of Health (2004) Hospital Episode <st1:place w:st=3D"on"><st1:City w:st=3D"=
on">Statistics</st1:City>,
 <st1:country-region w:st=3D"on">England</st1:country-region></st1:place>:<=
o:p></o:p></span></p>

<p class=3DGR-No-Indent-Normal><span style=3D'mso-bidi-font-size:8.5pt'>Fin=
ancial
Year 2003&#8211;04. Available at: http://www.dh.gov.uk.<o:p></o:p></span></=
p>

</div>

</body>

</html>

------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430_files/image001.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430_files/image002.jpg
Content-Transfer-Encoding: base64
Content-Type: image/jpeg
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------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430_files/image003.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430_files/image004.jpg
Content-Transfer-Encoding: base64
Content-Type: image/jpeg
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------=_NextPart_01C8B4FF.3EF4A620
Content-Location: file:///C:/A398D690/tonsillectomy-080430_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../tonsillectomy-080430.htm"/>
 <o:File HRef=3D"image001.png"/>
 <o:File HRef=3D"image002.jpg"/>
 <o:File HRef=3D"image003.png"/>
 <o:File HRef=3D"image004.jpg"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01C8B4FF.3EF4A620--
